In vitro study shows enhanced cytotoxicity and migration inhibition in osteosarcoma cells using microRNA-143-armed oncolytic virus, suggesting a potent bone cancer strategy.
Background: Attempts have been made to enhance systemic therapy for osteosarcoma. In our previous study, the systemic administration of a vesicular stomatitis virus (VSV) improved the survival rates of mice with osteosarcoma but did not improve the long-term survival of the animals. Materials and Methods: In the present study, we developed a novel oncolytic VSV by incorporating tumor-suppressor microRNA143 (rVSV-miR143) to compare the antitumor effects of various doses (10×10⁻⁴, 5×10⁻⁴, and 1×10⁻⁴ multiplicity of infection) of rVSV-miR143 with those of VSV in vitro. Results: The cytotoxicity and migration-inhibitory effects of rVSV-miR143 on the osteosarcoma cells were significantly higher than those of VSV alone at a dose of 5×10⁻⁴ multiplicity of infection, indicating that rVSV-miRNA143 enhances the antitumor effect at certain doses. Conclusion: VSV incorporating tumor-suppressor miRNA143 demonstrated a synergistic antitumor effect on osteosarcoma cells in vitro.
No takes yet. Share an insight, caveat, or question.
Sakuda et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: